Edition:
United Kingdom

Granules India Ltd (GRAN.NS)

GRAN.NS on National Stock Exchange of India

91.55INR
6:14am BST
Change (% chg)

Rs-3.45 (-3.63%)
Prev Close
Rs95.00
Open
Rs95.05
Day's High
Rs95.70
Day's Low
Rs91.40
Volume
1,422,535
Avg. Vol
1,907,592
52-wk High
Rs151.40
52-wk Low
Rs91.20

Chart for

About

Granules India Limited is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The Company's business operations include three areas: core business, emerging... (more)

Overall

Beta: 1.09
Market Cap(Mil.): Rs26,179.48
Shares Outstanding(Mil.): 253.84
Dividend: 0.25
Yield (%): 1.05

Financials

  GRAN.NS Industry Sector
P/E (TTM): 13.98 28.57 32.53
EPS (TTM): 6.80 -- --
ROI: -- 13.08 12.63
ROE: -- 14.80 14.50

BRIEF-Granules India Gets One Form 483 Observation For Jeedimeetla Facility

* GAGILLAPUR, JEEDIMETLA FACILITIES COMPLETED U.S. FDA INSPECTION; NO 483 OBSERVATION FOR GAGILLAPUR; 1 OBSERVATION FOR JEEDIMEETLA Source text - http://bit.ly/2G5IloH Further company coverage:

26 Mar 2018

BRIEF-Granules India Says U.S. FDA Approves ANDA For Metformin Extended Release Tablets

* USFDA APPROVED ANDA FILED BY CO FOR METFORMIN EXTENDED RELEASE (ER) TABLETS 500 MG AND 750 MG

19 Mar 2018

BRIEF-Granules India Says U.S. FDA Issued EIR For Unit's Facility In Virginia

* SAYS U.S. FDA ISSUED EIR FOR GRANULES PHARMA FACILITY IN CHANTILLY, VIRGINIA

28 Feb 2018

BRIEF-Granules India Dec Qtr Consol Profit Falls

* DEC QUARTER CONSOL NET PROFIT 350.2 MILLION RUPEES VERSUS 390.6 MILLION RUPEES YEAR AGO

08 Feb 2018

BRIEF-Granules India's Virginia Unit Completes U.S. FDA Audit With 1 Observation

* SAYS GRANULES PHARMACEUTICALS COMPLETES U.S. FDA INSPECTION WITH 1 OBSERVATION Source text: http://bit.ly/2AK3Fdu Further company coverage:

11 Dec 2017

Earnings vs. Estimates